Cargando…

ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis

OBJECTIVE: To explore the relationship between ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in ovarian cancer by the method of meta-analysis. METHODS: Pubmed, Web of Science, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), and China Wanfang databases we...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yuqiang, Cao, Sufen, Zhuang, Chunyu, Chen, Jiacheng, Chen, Xiaojing, Sun, Hong, Lin, Shengying, Lin, Bailang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215742/
https://www.ncbi.nlm.nih.gov/pubmed/34148553
http://dx.doi.org/10.1186/s13048-021-00831-y
_version_ 1783710298484506624
author Zhang, Yuqiang
Cao, Sufen
Zhuang, Chunyu
Chen, Jiacheng
Chen, Xiaojing
Sun, Hong
Lin, Shengying
Lin, Bailang
author_facet Zhang, Yuqiang
Cao, Sufen
Zhuang, Chunyu
Chen, Jiacheng
Chen, Xiaojing
Sun, Hong
Lin, Shengying
Lin, Bailang
author_sort Zhang, Yuqiang
collection PubMed
description OBJECTIVE: To explore the relationship between ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in ovarian cancer by the method of meta-analysis. METHODS: Pubmed, Web of Science, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), and China Wanfang databases were comprehensively searched up to September 2020, to identify the relationship between ERCC1 rs11615 polymorphism and chemosensitivity of ovarian cancer. The data was analyzed by Stata 15.0 statistic software. RESULTS: A total of 10 published papers were included, including 1866 patients with ovarian cancer. The results showed that compared allele C at ERCC1 rs11615 locus with allele T, the pooled OR was 0.92 (95%CI:0.68 ~ 1.24, P > 0.05). There were no significant differences in recessive, dominant, homozygous, and heterozygous models. In accordance with a subgroup analysis of Ethnicity, all genotypes were statistically significant in the Asian population. In the allelic, dominant, recessive, homozygous and heterozygous models, the OR was 0.70 (95%CI:0.51 ~ 0.95), 0.20 (95%CI:0.07 ~ 0.56), 0.79 (95%CI:0.63 ~ 1.00), 0.21 (95%CI:0.07 ~ 0.59), 0.19 (95%CI:0.07 ~ 0.54), respectively, while in the Caucasian population, no statistically significant genotype was found. CONCLUSION: The ERCC1 rs11615 polymorphism is associated with chemosensitivity in patients with ovarian cancer, especially in the Asian population, but not in the Caucasian population.
format Online
Article
Text
id pubmed-8215742
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82157422021-06-23 ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis Zhang, Yuqiang Cao, Sufen Zhuang, Chunyu Chen, Jiacheng Chen, Xiaojing Sun, Hong Lin, Shengying Lin, Bailang J Ovarian Res Review OBJECTIVE: To explore the relationship between ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in ovarian cancer by the method of meta-analysis. METHODS: Pubmed, Web of Science, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), and China Wanfang databases were comprehensively searched up to September 2020, to identify the relationship between ERCC1 rs11615 polymorphism and chemosensitivity of ovarian cancer. The data was analyzed by Stata 15.0 statistic software. RESULTS: A total of 10 published papers were included, including 1866 patients with ovarian cancer. The results showed that compared allele C at ERCC1 rs11615 locus with allele T, the pooled OR was 0.92 (95%CI:0.68 ~ 1.24, P > 0.05). There were no significant differences in recessive, dominant, homozygous, and heterozygous models. In accordance with a subgroup analysis of Ethnicity, all genotypes were statistically significant in the Asian population. In the allelic, dominant, recessive, homozygous and heterozygous models, the OR was 0.70 (95%CI:0.51 ~ 0.95), 0.20 (95%CI:0.07 ~ 0.56), 0.79 (95%CI:0.63 ~ 1.00), 0.21 (95%CI:0.07 ~ 0.59), 0.19 (95%CI:0.07 ~ 0.54), respectively, while in the Caucasian population, no statistically significant genotype was found. CONCLUSION: The ERCC1 rs11615 polymorphism is associated with chemosensitivity in patients with ovarian cancer, especially in the Asian population, but not in the Caucasian population. BioMed Central 2021-06-21 /pmc/articles/PMC8215742/ /pubmed/34148553 http://dx.doi.org/10.1186/s13048-021-00831-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Zhang, Yuqiang
Cao, Sufen
Zhuang, Chunyu
Chen, Jiacheng
Chen, Xiaojing
Sun, Hong
Lin, Shengying
Lin, Bailang
ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis
title ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis
title_full ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis
title_fullStr ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis
title_full_unstemmed ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis
title_short ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis
title_sort ercc1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215742/
https://www.ncbi.nlm.nih.gov/pubmed/34148553
http://dx.doi.org/10.1186/s13048-021-00831-y
work_keys_str_mv AT zhangyuqiang ercc1rs11615polymorphismandchemosensitivitytoplatinumdrugsinpatientswithovariancancerasystematicreviewandmetaanalysis
AT caosufen ercc1rs11615polymorphismandchemosensitivitytoplatinumdrugsinpatientswithovariancancerasystematicreviewandmetaanalysis
AT zhuangchunyu ercc1rs11615polymorphismandchemosensitivitytoplatinumdrugsinpatientswithovariancancerasystematicreviewandmetaanalysis
AT chenjiacheng ercc1rs11615polymorphismandchemosensitivitytoplatinumdrugsinpatientswithovariancancerasystematicreviewandmetaanalysis
AT chenxiaojing ercc1rs11615polymorphismandchemosensitivitytoplatinumdrugsinpatientswithovariancancerasystematicreviewandmetaanalysis
AT sunhong ercc1rs11615polymorphismandchemosensitivitytoplatinumdrugsinpatientswithovariancancerasystematicreviewandmetaanalysis
AT linshengying ercc1rs11615polymorphismandchemosensitivitytoplatinumdrugsinpatientswithovariancancerasystematicreviewandmetaanalysis
AT linbailang ercc1rs11615polymorphismandchemosensitivitytoplatinumdrugsinpatientswithovariancancerasystematicreviewandmetaanalysis